271 related articles for article (PubMed ID: 32661269)
1. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease.
Wan N; Rahman A; Nishiyama A
J Hum Hypertens; 2021 Feb; 35(2):148-156. PubMed ID: 32661269
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).
Takahashi M; Ubukata O; Homma T; Asoh Y; Honzumi M; Hayashi N; Saito K; Tsuruoka H; Aoki K; Hanzawa H
FEBS Lett; 2020 May; 594(10):1615-1623. PubMed ID: 31991486
[TBL] [Abstract][Full Text] [Related]
4. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.
Bhuiyan AS; Rafiq K; Kobara H; Masaki T; Nakano D; Nishiyama A
Hypertens Res; 2019 Jun; 42(6):892-902. PubMed ID: 30664703
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro
Yamakawa S; Homma T; Yamada M; Igawa Y; Yoshimura M
Nihon Yakurigaku Zasshi; 2020; 155(5):340-350. PubMed ID: 32879177
[TBL] [Abstract][Full Text] [Related]
6. Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study.
Kario K; Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
Am J Hypertens; 2021 May; 34(5):540-551. PubMed ID: 33165570
[TBL] [Abstract][Full Text] [Related]
7. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
Arai K; Morikawa Y; Ubukata N; Sugimoto K
Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
[TBL] [Abstract][Full Text] [Related]
8. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).
Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
Hypertension; 2020 Jan; 75(1):51-58. PubMed ID: 31786983
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.
Satoh F; Ito S; Itoh H; Rakugi H; Shibata H; Ichihara A; Omura M; Takahashi K; Okuda Y; Iijima S
Hypertens Res; 2021 Apr; 44(4):464-472. PubMed ID: 33199881
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study.
Iwahana T; Saito Y; Okada S; Kato H; Ono R; Kobayashi Y
PLoS One; 2021; 16(11):e0259485. PubMed ID: 34748605
[TBL] [Abstract][Full Text] [Related]
11. Role of mineralocorticoid receptor antagonists in kidney diseases.
Patel V; Joharapurkar A; Jain M
Drug Dev Res; 2021 May; 82(3):341-363. PubMed ID: 33179798
[TBL] [Abstract][Full Text] [Related]
12. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
Li L; Guan Y; Kobori H; Morishita A; Kobara H; Masaki T; Nakano D; Nishiyama A
Hypertens Res; 2019 Jun; 42(6):769-778. PubMed ID: 30587856
[TBL] [Abstract][Full Text] [Related]
13. The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers.
Tezuka Y; Ito S
Curr Hypertens Rep; 2022 Jul; 24(7):215-224. PubMed ID: 35488944
[TBL] [Abstract][Full Text] [Related]
14. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.
Rakugi H; Yamakawa S; Sugimoto K
Hypertens Res; 2021 Apr; 44(4):371-385. PubMed ID: 33214722
[TBL] [Abstract][Full Text] [Related]
15. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1715-1727. PubMed ID: 33239409
[TBL] [Abstract][Full Text] [Related]
16. Esaxerenone: First Global Approval.
Duggan S
Drugs; 2019 Mar; 79(4):477-481. PubMed ID: 30806972
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Ito S; Shikata K; Nangaku M; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2019 Aug; 14(8):1161-1172. PubMed ID: 31248950
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats.
Rahman A; Sawano T; Sen A; Hossain A; Jahan N; Kobara H; Masaki T; Kosaka S; Kitada K; Nakano D; Imamura T; Ohsaki H; Nishiyama A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669786
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction.
Ito S; Itoh H; Rakugi H; Okuda Y; Iijima S
Hypertens Res; 2021 May; 44(5):489-497. PubMed ID: 33323991
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.
Sueta D; Yamamoto E; Tsujita K
Curr Hypertens Rep; 2020 Feb; 22(3):21. PubMed ID: 32114686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
